IRCT20190708044158N1CompletedPhase 3
Comparison between the Effect of Fenofibrate and Clofibrate on Term Neonates with Hyperbilirubinemia
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 80
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 3 days to 28 days (—)
- Sex
- All
Inclusion Criteria
- •Term neonates(37 weeks to 41 weeks and 6 days) that their ages are more than 72 hours.
- •They were admitted for jaundice, total bilirubin serum more than 15 mg/dl.
- •They were otherwise healthy.
- •They did not receive therapy other than phototherapy.
Exclusion Criteria
- •Premature neonates
- •IUGR infants
- •Neonates with congenital anomaly
- •Neonates with blood group and RH incompatibility
- •Neonates with G6PD deficiency
- •Neonates with history of maternal phenobarbital consumption
- •Neonates with respiratory distress and signs and symptoms of sepsis
Investigators
Similar Trials
Completed
Not Applicable
Comparison of therapeutic effects of Fenofibrate and Gemfibrozil on Lipid in patients with DiabetesIRCT201401096710N4Research deputy of Tabriz University of Medical Sciences60
Completed
Phase 4
A CLINICAL TRIAL ON EFFECT OF SINGLE DOSE FENOFIBRATE AS AN ADJUNCT TO PHOTOTHERAPY IN NEONATAL JAUNDICECTRI/2023/03/050811Deepaa S94
Completed
Phase 3
Fenofibrate in PSCIRCT20200427047225N1Shahid Beheshti University of Medical Sciences30
Completed
Not Applicable
Prevention effect of fenofibrate/pioglitazone in obese diabetic patientsNutritional, Metabolic, EndocrineT2DM, obesityPACTR201407000856135faculty of pharmacy, ain shams university60
Completed
Phase 3
Evaluation of efficacy and safety of Fenofibrate in COVID-19 patientsIRCT20220612055149N1Artesh University of Medical Sciences70